Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are at least 18 years old at the time of signing the study consent form
- People who have a tissue-confirmed diagnosis of a well-differentiated (slow-growing) neuroendocrine tumour (NET) that has spread or cannot be surgically removed — this applies across various tumour locations, including the gut, pancreas, lungs, thyroid, breast, urogenital system, and adrenal glands (for the initial dose-testing phase)
- People with a confirmed well-differentiated NET originating in the gut or pancreas that has spread or cannot be surgically removed (for one specific expansion group)
- People with a confirmed well-differentiated NET from sites other than the gut or pancreas, or a confirmed meningioma (a type of brain/skull tumour), that has spread or cannot be surgically removed — where the tumour is known to frequently carry a specific protein called SSTR (for another expansion group)
- People whose tumour shows positive results on a specific type of scan that detects the SSTR protein
- People whose kidneys, blood, and liver are functioning at an adequate level
Who may not be able to join:
- People who have previously received a type of treatment called radioligand or radiopeptide therapy, including a treatment known as Lu-177
- People who have previously had a solid organ transplant or bone marrow transplant
- People who use steroid medication on an ongoing, long-term basis taken throughout the whole body (not just topically)
- People with significant heart or cardiovascular disease
- People with high blood pressure that has not responded to treatment
- People with diabetes that is not well controlled
- People with a prior history of liver cirrhosis (severe liver scarring)
- People who have HIV, hepatitis B, or a currently active hepatitis C infection
Important: Always verify eligibility with the trial site directly before applying. Additional criteria may also apply and will be assessed by the study site.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ye Yuan, MD, RayzeBio, Inc.
Phone: +1 619 657 0057
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose Escalation; Dose Expansion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.